113P - Palliative radiation during pemetrexed plus cisplatin first-line treatment for advanced non-small cell lung cancer (NSCLC): patient safety in the JM...

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Metastatic
Surgery and/or Radiotherapy of Cancer
Presenter Giorgio Scagliotti
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors G.V. Scagliotti1, C. Gridelli2, F. de Marinis3, B. Biesma4, M. Reck5, B. San Antonio6, A.H. Zimmermann7, C. Visseren-Grul8, N. Chouaki9, L. Paz-Ares10
  • 1Clinical And Biological Sciences, University of Torino, 10043 - Torino/IT
  • 2Dept Oncology / Hematology, San Giuseppe Moscati Hospital, Avellino/IT
  • 3First Oncological Pulmonary Unit, San Camillo Forlanini Hospital, Rome/IT
  • 4Dept Pulmonary Diseases, Jeroen Bosch Hospital, Hertogenbosch/NL
  • 5Thoracic Oncology, Hospital Grosshansdorf, 22927 - Grosshansdorf/DE
  • 6Oncology, Eli Lilly and Company, Madrid/ES
  • 7Oncology, Eli Lilly and Company, Indianapolis/US
  • 8Oncology - Thoracic, Eli Lilly and Company, Houten/NL
  • 9Oncology - Thoracic, Eli Lilly and Company, Paris/FR
  • 10Oncology, Seville University Hospital, Seville/ES


The safety of palliative radiation (XRT) during first-line treatment with pemetrexed (Pem) plus cisplatin (Cis) was studied in a subset of pts in the JMDB (DB) and PARAMOUNT (PM) Phase 3 trials. Pts with stage IIIB/IV nonsquamous (NS) NSCLC (DB, n=618; PM, n=939) received up to 6 cycles and up to 4 cycles of induction therapy with Pem/Cis, respectively.